To the Editor:
Cardiovascular disease (CVD) is common in patients with chronic obstructive pulmonary disease (COPD) (1) (2) (3) (4) , yet it is unclear whether its presence increases the incidence of acute exacerbations (AECOPD) or the risk of death. Observational studies have shown that COPD is associated with a two to five times higher risk of ischemic heart disease (IHD), cardiac dysrhythmia, heart failure, diseases of the pulmonary circulation, and diseases of the arteries compared with non-COPD populations (4, 5) . A prospective evaluation of COPD exacerbations in patients with comorbid IHD from the London COPD Cohort reported longer duration but not increased frequency of AECOPD in patients with IHD (6) .
This prospective study was designed to test the hypothesis that the presence of CVD increases the risk AECOPD and/or death in patients with COPD recruited in a primary care setting.
Methods
The ACCESS (Assessment of Comorbidities in COPD in European Symptomatic Subjects) study (NCT01516528; GlaxoSmithKline study 115058) was a prospective, longitudinal, observational, nondrug interventional, 2-year study in patients with COPD enrolled from primary care in Belgium, France, Germany, the Netherlands, Poland, and Spain. Patients visiting their general practitioner for any reason were invited to participate if they were 40 years old or older, a current or ex-smoker (smoking history of >10 pack-years), had a minimum of 12 months of prior history of COPD, and had a FEV 1 /FVC postbronchodilator ratio less than 0.70. Patients with a primary diagnosis of asthma, pulmonary fibrosis, asbestosis, any cancer, or clinically significant bronchiectasis were excluded.
Patients were followed up for 27 months through clinic visits at screening (23 mo), baseline (0 mo), 12 months, and 24 months, and by phone at 3, 6, 9, 15, 18, and 21 months. Written informed consent was obtained from all subjects, and the study was approved by independent ethics committees as per the requirements in each country.
The prevalence of CVD at baseline was defined using a composite measure with previously published criteria (7). The primary outcome was the annual rate of moderate to severe AECOPD during the 24-month follow-up period. Moderate AECOPD was defined as a worsening of symptoms that required oral corticosteroids and/or antibiotics, whereas severe exacerbations were defined as those that included hospitalization. Mortality was a secondary outcome; details of patient deaths were obtained from the general practitioner.
To derive event rates and test associations, we applied multivariable negative binomial regression and Cox proportional hazards regression models, respectively. All analysis was prespecified except hospitalizations and mortality outcome modeling, which were post hoc.
Results
This analysis included 2,887 evaluable patients. Their mean age was 66 years, 70% were men, and 47% were current smokers with a mean postbronchodilator FEV 1 % predicted of approximately 60% ( Table 1 ). The mean number of moderate to severe AECOPD episodes in the previous year was 0.61 (95% confidence interval [CI], 0.57-0.64); for severe AECOPD, it was 0.08 (95% CI, 0.07-0.09). At baseline, patients with COPD with CVD (1,375; 48%) were older and more likely to be ex-smokers but had a similar airflow limitation and history of exacerbations to those without CVD.
Over the course of 24 months, there was no difference in the annualized rate of AECOPD between those with or without CVD (adjusted rate per patient, 0. Table 2 ). Male sex, lower postbronchodilator FEV 1 % predicted, and higher COPD Assessment Test score, but not older age, were significantly independently associated with a higher overall rate of exacerbations. Addition of history of AECOPD events in the 12 months before study baseline into models was significantly associated with the rate during the study, but it did not change the effect of CVD on this outcome (rate ratio, 1.01; 95% CI, 0.90-1.12). In addition, a sensitivity analysis for each CVD diagnosis from the composite CVD definition did not show any relationship between individual CV diseases and the incidence of AECOPD.
The unadjusted annual rate of severe exacerbations (requiring hospitalization) was 51% higher in patients with CVD than in those with no CVD (rate ratio, 1.51; 95% CI, 1.16-1.97; P = 0.003).
In the adjusted multivariable model, this trend was not statistically significant (rate ratio, 1.14; 95% CI, 0.87-1.50) ( Table 2 ). Patients with one or more event, n (%) 113 (8) 68 (4) 181 ( 
Discussion
This is the first large-scale study to prospectively evaluate the relationship between CVD and exacerbation rates and mortality in a well-characterized cohort of patients with COPD. Although on average, the patients were relatively mild in terms of lung function impairment, COPD Assessment Test score, and exacerbation rate, the cohort did contain the whole range of disease severity. We found that the presence of CVD was not independently associated with an increased risk for exacerbations or death. This finding was not expected in view of prior evidence that there was a link (8) (9) (10) . There are at least two reasons to explain this difference. Some earlier studies had methodological limitations; for example, two were retrospective and used data extracted from routine electronic medical records. Furthermore, it is also important to understand temporal associations and mechanisms of causality. For example, patients hospitalized for AECOPD are at increased risk for myocardial infarction after admission (11, 12) , and case series data provide evidence of a link through viral infections, which may trigger both AECOPD and vascular events (13, 14) .
It is conceivable that within this primary care population, there was an insufficient number of patients of a particular phenotype in whom a link does exist, or patients who did not have sufficiently severe COPD to demonstrate the link, but the sample was large and the rate ratio was very close to 1.0, so the likelihood of this being a factor is low. We conclude that there is little or no evidence that the presence of CVD in patients with COPD increases the risk for exacerbations or death, but it may increase the risk for hospitalization. n Author disclosures are available with the text of this letter at www.atsjournals.org.
Can the WIND Definition Classify All Invasively Ventilated Patients?
To the Editor:
We read with great interest the study by Béduneau and colleagues (1), wherein the authors described the WIND (Weaning According to a New Definition) definition for weaning among invasively ventilated patients and evaluated associated prognosis. We absolutely agree that the WIND definition can classify more ventilated patients than the International Consensus Conference definition does (2) . However, we provide the following comments.
First, the text description of the WIND classification for short weaning and difficult weaning disagreed with those indicated in the schematic diagram (Figure 2 in Reference 1). To be specific, the WIND classification defined short weaning (group 1) and difficult weaning (group 2) terminating within 1 day (24 h) and after more than 1 day but in less than 1 week after the first attempt at weaning or separation, respectively, whereas Figure 2 showed that short weaning and difficult weaning covered Day 0 to Day 1 (2 d) and Day 2 to Day 6 (5 d), respectively. We think time span (,24 h, 24 h to z168 h, .168 h) could describe their definition more clearly. On the other hand, we recommend calendar days for classifying the weaning process, which might have better operability in clinical practice, referring to the ventilator-associated event definition (3).
Second, the authors declared the new definition can classify all patients. In fact, it cannot. According to their classification of four groups, the patients who were discharged alive under invasive ventilation from the ICU within 1 week after the first separation attempt could not be classified. In their study, there were four discharges alive under invasive ventilation (two with intubation, two with tracheostomy) who had been wrongly classified in group 1 and in group 2 ( Table 2 in Reference 1) .
Third, according to their inclusion criteria for patients newly admitted during the study period and requiring intubation for ventilation, the authors missed the tracheostomized patients admitted to the ICU for invasive ventilation. This violated the goal of the WIND definition, namely fitting daily practice and being operational for every ventilated patient in various environments.
Finally, in our experience, there could be some patients who experienced two or more successful separations during the same ICU stay. The authors did not mention this kind of patient. How should we classify them? What is their prognosis?
We think the WIND definition will be more practicable after clarifying these comments. n
